PT4219487T - Agonistas dos recetores glp-1 e utilizações dos mesmos - Google Patents

Agonistas dos recetores glp-1 e utilizações dos mesmos

Info

Publication number: PT4219487T
Authority: PT; Portugal
Prior art keywords: glp; receptor agonists; agonists; receptor
Prior art date: 2018-06-13

Application number

PT231557471T

Other languages

English (en)

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-06-13

Filing date

2019-06-11

Publication date

2025-02-18

2019-06-11 Application filed by Pfizer filed Critical Pfizer

2025-02-18 Publication of PT4219487T publication Critical patent/PT4219487T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
- C07C53/06—Salts thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)

PT231557471T 2018-06-13 2019-06-11 Agonistas dos recetores glp-1 e utilizações dos mesmos PT4219487T (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201862684696P	2018-06-13	2018-06-13
US201962846944P	2019-05-13	2019-05-13
US201962851206P	2019-05-22	2019-05-22

Publications (1)

Publication Number	Publication Date
PT4219487T true PT4219487T (pt)	2025-02-18

Family

ID=67003576

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT231557471T PT4219487T (pt)	2018-06-13	2019-06-11	Agonistas dos recetores glp-1 e utilizações dos mesmos
PT197331515T PT3806955T (pt)	2018-06-13	2019-06-11	Agonistas dos receptores glp-1 e suas utilizações

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT197331515T PT3806955T (pt)	2018-06-13	2019-06-11	Agonistas dos receptores glp-1 e suas utilizações

Country Status (38)

Country	Link
US (5)	US10934279B2 (pt)
EP (2)	EP3806955B9 (pt)
JP (1)	JP6916968B1 (pt)
KR (1)	KR102542199B1 (pt)
CN (4)	CN119462621A (pt)
AU (1)	AU2019285491B2 (pt)
BR (1)	BR112020024470A2 (pt)
CA (1)	CA3045644C (pt)
CL (1)	CL2020003222A1 (pt)
CO (1)	CO2020015305A2 (pt)
CR (1)	CR20200612A (pt)
CU (1)	CU20200099A7 (pt)
CY (1)	CY1126097T1 (pt)
DK (2)	DK3806955T3 (pt)
EC (1)	ECSP20078651A (pt)
ES (1)	ES2949954T3 (pt)
FI (2)	FI3806955T3 (pt)
GE (1)	GEP20237453B (pt)
HR (2)	HRP20230631T1 (pt)
HU (1)	HUE063074T2 (pt)
IL (1)	IL279300B2 (pt)
LT (2)	LT4219487T (pt)
MD (1)	MD3806955T3 (pt)
MX (1)	MX2020013625A (pt)
NI (1)	NI202000091A (pt)
NZ (1)	NZ770240A (pt)
PE (2)	PE20240584A1 (pt)
PH (1)	PH12020552069A1 (pt)
PL (1)	PL3806955T3 (pt)
PT (2)	PT4219487T (pt)
RS (2)	RS66418B1 (pt)
SG (1)	SG11202011465QA (pt)
SI (1)	SI3806955T1 (pt)
TW (1)	TWI707683B (pt)
UA (1)	UA124371C2 (pt)
UY (1)	UY38261A (pt)
WO (1)	WO2019239319A1 (pt)
ZA (1)	ZA202007572B (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10934279B2 (en) *	2018-06-13	2021-03-02	Pfizer Inc.	GLP-1 receptor agonists and uses thereof
ES2943510T3 (es)	2018-06-15	2023-06-13	Pfizer	Agonistas del receptor GLP-1 y usos del mismo
PE20211871A1 (es) *	2018-11-22	2021-09-21	Qilu Regor Therapeutics Inc	Agonistas de glp-1r y usos de los mismos
US10954221B2 (en)	2019-04-12	2021-03-23	Qilu Regor Therapeutics Inc.	GLP-1R agonists and uses thereof
WO2020234726A1 (en) *	2019-05-20	2020-11-26	Pfizer Inc.	Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TWI751585B (zh) *	2019-06-28	2022-01-01	美商美國禮來大藥廠	類升糖素肽1受體促效劑
PE20221040A1 (es)	2019-10-25	2022-06-17	Gilead Sciences Inc	Compuestos moduladores de glp-1r
US20230045419A1 (en) *	2019-12-10	2023-02-09	Pfizer Inc.	Solid Forms of 2-((4-((S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt
US12121511B2 (en) *	2020-01-29	2024-10-22	Gilead Sciences, Inc.	GLP-1R modulating compounds
ES2986788T3 (es)	2020-02-07	2024-11-12	Gasherbrum Bio Inc	Agonistas heterocíclicos de GLP-1
CN113493447B (zh) *	2020-04-03	2024-06-11	轩竹(北京)医药科技有限公司	Glp-1受体激动剂
TW202144340A (zh) *	2020-04-03	2021-12-01	大陸商江蘇恆瑞醫藥股份有限公司	稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
CN115667250A (zh) *	2020-04-29	2023-01-31	加舒布鲁姆生物公司	杂环glp-1激动剂
EP4166142A4 (en) *	2020-06-10	2024-06-26	Medshine Discovery Inc.	METHYL-SUBSTITUTED BENZOBISOXAZOLE COMPOUND AND USE THEREOF
CN113816948B (zh) *	2020-06-19	2023-08-11	江苏恒瑞医药股份有限公司	稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN115916772B (zh) *	2020-06-19	2025-01-14	江苏恒瑞医药股份有限公司	6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
WO2022031994A1 (en) *	2020-08-06	2022-02-10	Qilu Regor Therapeutics Inc.	Glp-1r agonists and uses thereof
IL300155A (en)	2020-08-06	2023-03-01	Gasherbrum Bio Inc	Heterocyclic GLP-1 agonists
CN116406360A (zh)	2020-08-28	2023-07-07	加舒布鲁姆生物公司	杂环glp-1激动剂
WO2022007979A1 (zh)	2020-09-01	2022-01-13	江苏恒瑞医药股份有限公司	稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2022068772A1 (zh) *	2020-09-29	2022-04-07	深圳信立泰药业股份有限公司	一种苯并咪唑类衍生物及其制备方法和医药用途
EP4229050A4 (en) *	2020-10-13	2024-12-11	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
CN114478694A (zh) *	2020-11-13	2022-05-13	成都奥达生物科技有限公司	一种长效mc4r激动剂
EP4247804A1 (en) *	2020-11-20	2023-09-27	Gilead Sciences, Inc.	Polyheterocyclic glp-1 r modulating compounds
US20240246959A1 (en)	2020-11-27	2024-07-25	Shenzhen Salubris Pharmaceuticals Co., Ltd.	Benzimidazole derivative and preparation method therefor and medical use thereof
CN114591308B (zh) *	2020-12-03	2024-03-08	苏州闻泰医药科技有限公司	一类glp-1r受体激动剂化合物及其用途
US12065434B2 (en)	2020-12-15	2024-08-20	Pfizer Inc.	Metabolites of GLP1R agonists
WO2022165076A1 (en) *	2021-01-28	2022-08-04	Carmot Therapeutics, Inc.	Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
WO2022184849A1 (en)	2021-03-04	2022-09-09	Les Laboratoires Servier	Glp-1r agonists, uses and pharmaceutical compositions thereof
EP4304712A1 (en)	2021-03-11	2024-01-17	Gilead Sciences, Inc.	Glp-1r modulating compounds
EP4304711A1 (en)	2021-03-11	2024-01-17	Gilead Sciences, Inc.	Glp-1r modulating compounds
JPWO2022202864A1 (pt)	2021-03-24	2022-09-29
WO2022219495A1 (en)	2021-04-12	2022-10-20	Novartis Ag	2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
EP4271672A1 (en)	2021-04-21	2023-11-08	Gilead Sciences, Inc.	Carboxy-benzimidazole glp-1r modulating compounds
WO2022228490A1 (zh) *	2021-04-30	2022-11-03	上海翰森生物医药科技有限公司	多环类衍生物调节剂、其制备方法和应用
CA3217720A1 (en) *	2021-05-03	2022-11-10	Xiaohui Du	Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
TWI843104B (zh)	2021-05-20	2024-05-21	美商美國禮來大藥廠	類升糖素肽1受體促效劑
JP2024525900A (ja) *	2021-07-21	2024-07-12	ヘパジーンセラピューティクス（エイチケー）リミティド	グルカゴン様ペプチド－１受容体モジュレーター及びその使用
CN113480534B (zh) *	2021-07-23	2022-05-13	广州必贝特医药股份有限公司	苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
US20240360109A1 (en) *	2021-08-04	2024-10-31	Shanghai Hansoh Biomedical Co., Ltd.	Cycloalkene derivative regulator, preparation method therefor, and application thereof
US20240368178A1 (en) *	2021-08-24	2024-11-07	Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd.	Imidazocyclic compound and application thereof
EP4400105A1 (en)	2021-09-08	2024-07-17	Shionogi & Co., Ltd	Medicine for prevention and treatment of diseases linked to anti-obesity activity
WO2023057414A1 (en) *	2021-10-05	2023-04-13	Astrazeneca Ab	Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
EP4412707A1 (en) *	2021-10-05	2024-08-14	Astrazeneca AB	Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
WO2023057429A1 (en)	2021-10-05	2023-04-13	Astrazeneca Ab	Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
CN115991685B (zh) *	2021-10-20	2025-03-04	韶远科技（上海)有限公司	一种氧杂环丁烷-2-甲胺的制备方法
TWI843243B (zh) *	2021-10-22	2024-05-21	大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司	作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途
IL312364A (en)	2021-10-25	2024-06-01	Luehr Gary W	Compounds as GLP-1R agonists
WO2023106310A1 (ja) *	2021-12-07	2023-06-15	塩野義製薬株式会社	Ｇｌｐ－１受容体アゴニスト活性を有する芳香族複素環誘導体
CN113974618B (zh) *	2021-12-12	2022-09-13	广西澍源智能科技有限公司	基于水峰血糖修正的无创血糖测试方法
WO2023111145A1 (en)	2021-12-16	2023-06-22	Astrazeneca Ab	Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111144A1 (en)	2021-12-16	2023-06-22	Astrazeneca Ab	Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
AU2022418658A1 (en) *	2021-12-23	2024-07-11	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method therefor
KR20240125004A (ko) *	2021-12-23	2024-08-19	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	Glp-1 수용체 작용제의 결정 형태 및 이의 제조방법
CN116354945B (zh) *	2021-12-27	2024-08-30	长春金赛药业有限责任公司	一种稠合咪唑羧酸类化合物及其制备方法和应用
WO2023151575A1 (en) *	2022-02-09	2023-08-17	Gasherbrum Bio Inc.	Heterocyclic glp-1 agonists
JP2025506473A (ja) *	2022-02-09	2025-03-11	ガシャーブラム・バイオ・インコーポレイテッド	ヘテロ環ｇｌｐ－１アゴニスト
EP4476212A1 (en)	2022-02-10	2024-12-18	Novartis AG	2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
KR20240148000A (ko) *	2022-02-28	2024-10-10	애슬레티스 바이오사이언스 코., 엘티디.	Glp-1r 조절 화합물
JP2025508097A (ja) *	2022-03-08	2025-03-21	広州市聯瑞制葯有限公司	ベンゾビシクロ系化合物及びその製造方法と応用
WO2023228023A1 (en)	2022-05-23	2023-11-30	Pfizer Inc.	Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
WO2024051749A1 (zh) *	2022-09-06	2024-03-14	德睿智药(苏州)新药研发有限公司	一种glp-1r激动剂化合物的多晶型物及其制备方法与用途
WO2024063143A1 (ja)	2022-09-22	2024-03-28	塩野義製薬株式会社	Ｇｌｐ－１受容体アゴニスト作用を有する縮合環化合物
WO2024102625A1 (en)	2022-11-11	2024-05-16	Eli Lilly And Company	Glucagon-like peptide 1 receptor agonists
WO2024107781A1 (en)	2022-11-16	2024-05-23	Eli Lilly And Company	Glucagon-like peptide 1 receptor agonists
WO2024160271A1 (zh) *	2023-02-02	2024-08-08	江苏豪森药业集团有限公司	一种环烯类化合物的盐、晶型及其制备方法和应用
WO2024214038A1 (en)	2023-04-14	2024-10-17	Pfizer Inc.	Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
CN118812522A (zh) *	2023-04-21	2024-10-22	苏州闻泰医药科技有限公司	一种glp-1r受体激动剂化合物盐、其晶型、其制备方法和应用
WO2025015268A1 (en)	2023-07-13	2025-01-16	Aconcagua Bio, Inc.	Modulators of calcitonin receptor and/or amylin receptor activity
WO2025015269A1 (en)	2023-07-13	2025-01-16	Aconcagua Bio, Inc.	Compounds, compositions, and methods
USD1011080S1 (en)	2023-07-28	2024-01-16	Voilasophy, Llc.	Yoga storage rack
US12234236B1 (en)	2023-09-14	2025-02-25	Ascletis Pharma (China) Co., Limited	GLP-1R agonist and therapeutic method thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
JPH08508030A (ja)	1993-03-18	1996-08-27	メルクシヤープエンドドームリミテツド	ベンゾイミダゾール誘導体
AR022303A1 (es)	1999-01-22	2002-09-04	Lundbeck & Co As H	Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
WO2001030330A2 (en)	1999-10-29	2001-05-03	Merck Sharp & Dohme Limited	Method to treat pain utilizing benzimidazole nmda/nr2b antagonists
EP1351936A1 (en)	2001-01-15	2003-10-15	Glaxo Group Limited	Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
EP1465635A4 (en) *	2002-01-10	2005-04-13	Neurogen Corp	MELANIN-CONCENTRATING HORMONIC RECEPTOR LIGANDS: SUBSTITUTED 2- (4-BENZYL-PIPERAZIN-1-YLMETHYL) AND 2- (4-BENZYL-DIAZEPAN-1-YLMETHYL) -1H-BENZOIMIDAZOLE ANALOGUES
US20040127504A1 (en) *	2002-09-06	2004-07-01	Cowart Marlon D.	Benzimidazoles that are useful in treating sexual dysfunction
MY140489A (en)	2003-12-26	2009-12-31	Eisai R&D Man Co Ltd	1,2-di (cyclic) substituted benzene compounds
GB0412467D0 (en)	2004-06-04	2004-07-07	Astrazeneca Ab	Chemical compounds
WO2008012623A1 (en)	2006-07-25	2008-01-31	Pfizer Products Inc.	Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
MX2011010347A (es)	2009-03-30	2011-11-29	Transtech Pharma Inc	Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
CH702192A1 (de)	2009-11-04	2011-05-13	New Dent Ag	Keramisches Implantat.
WO2011097491A1 (en)	2010-02-04	2011-08-11	Glaxosmithkline Llc	Benzimidazole antiviral agents
NZ603876A (en) *	2010-05-13	2015-02-27	Amgen Inc	Nitrogen heterocyclic compounds useful as pde10 inhibitors
WO2012042433A1 (en)	2010-09-30	2012-04-05	Pfizer Inc.	N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
CU24152B1 (es)	2010-12-20	2016-02-29	Irm Llc	1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
CA2901577A1 (en)	2013-02-18	2014-08-21	The Scripps Research Institute	Modulators of vasopressin receptors with therapeutic potential
WO2016029146A1 (en)	2014-08-22	2016-02-25	University Of Washington	Specific inhibitors of methionyl-trna synthetase
WO2017066705A1 (en)	2015-10-14	2017-04-20	Aquinnah Pharmaceuticals, Inc.	Compounds, compositions and methods of use against stress granules
PL3397631T3 (pl)	2015-12-29	2021-09-20	Pfizer Inc.	Podstawione 3-azabicyklo[3.1.0]heksany jako inhibitory ketoheksokinazy
AR109179A1 (es)	2016-08-19	2018-11-07	Pfizer	Inhibidores de diacilglicerol aciltransferasa 2
JOP20190060A1 (ar)	2016-09-26	2019-03-26	Chugai Pharmaceutical Co Ltd	مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CN106271089B (zh)	2016-09-30	2019-01-25	英诺激光科技股份有限公司	一种激光薄膜刻蚀装置及方法
US10934279B2 (en) *	2018-06-13	2021-03-02	Pfizer Inc.	GLP-1 receptor agonists and uses thereof
WO2020234726A1 (en) *	2019-05-20	2020-11-26	Pfizer Inc.	Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases

2019
- 2019-06-10 US US16/436,311 patent/US10934279B2/en active Active
- 2019-06-10 CA CA3045644A patent/CA3045644C/en active Active
- 2019-06-10 TW TW108119890A patent/TWI707683B/zh active
- 2019-06-11 PT PT231557471T patent/PT4219487T/pt unknown
- 2019-06-11 FI FIEP19733151.5T patent/FI3806955T3/fi active
- 2019-06-11 RS RS20250036A patent/RS66418B1/sr unknown
- 2019-06-11 CN CN202411488573.3A patent/CN119462621A/zh active Pending
- 2019-06-11 IL IL279300A patent/IL279300B2/en unknown
- 2019-06-11 UA UAA202007608A patent/UA124371C2/uk unknown
- 2019-06-11 AU AU2019285491A patent/AU2019285491B2/en active Active
- 2019-06-11 CN CN202411489409.4A patent/CN119431342A/zh active Pending
- 2019-06-11 KR KR1020217000940A patent/KR102542199B1/ko active Active
- 2019-06-11 NZ NZ770240A patent/NZ770240A/en unknown
- 2019-06-11 HU HUE19733151A patent/HUE063074T2/hu unknown
- 2019-06-11 FI FIEP23155747.1T patent/FI4219487T3/fi active
- 2019-06-11 MD MDE20210363T patent/MD3806955T3/ro unknown
- 2019-06-11 EP EP19733151.5A patent/EP3806955B9/en active Active
- 2019-06-11 DK DK19733151.5T patent/DK3806955T3/da active
- 2019-06-11 HR HRP20230631TT patent/HRP20230631T1/hr unknown
- 2019-06-11 BR BR112020024470-8A patent/BR112020024470A2/pt unknown
- 2019-06-11 GE GEAP201915517A patent/GEP20237453B/en unknown
- 2019-06-11 PL PL19733151.5T patent/PL3806955T3/pl unknown
- 2019-06-11 DK DK23155747.1T patent/DK4219487T3/da active
- 2019-06-11 ES ES19733151T patent/ES2949954T3/es active Active
- 2019-06-11 SG SG11202011465QA patent/SG11202011465QA/en unknown
- 2019-06-11 JP JP2020569190A patent/JP6916968B1/ja active Active
- 2019-06-11 HR HRP20250099TT patent/HRP20250099T1/hr unknown
- 2019-06-11 PE PE2023003553A patent/PE20240584A1/es unknown
- 2019-06-11 RS RS20230504A patent/RS64323B9/sr unknown
- 2019-06-11 MX MX2020013625A patent/MX2020013625A/es unknown
- 2019-06-11 PT PT197331515T patent/PT3806955T/pt unknown
- 2019-06-11 CN CN202411489408.XA patent/CN119462622A/zh active Pending
- 2019-06-11 LT LTEP23155747.1T patent/LT4219487T/lt unknown
- 2019-06-11 SI SI201930570T patent/SI3806955T1/sl unknown
- 2019-06-11 CR CR20200612A patent/CR20200612A/es unknown
- 2019-06-11 EP EP23155747.1A patent/EP4219487B9/en active Active
- 2019-06-11 WO PCT/IB2019/054867 patent/WO2019239319A1/en active Application Filing
- 2019-06-11 LT LTEPPCT/IB2019/054867T patent/LT3806955T/lt unknown
- 2019-06-11 PE PE2020001993A patent/PE20211601A1/es unknown
- 2019-06-11 CN CN201980053632.5A patent/CN112533674B/zh active Active
- 2019-06-11 CU CU2020000099A patent/CU20200099A7/es unknown
- 2019-06-12 UY UY0001038261A patent/UY38261A/es unknown
- 2019-08-08 US US16/535,616 patent/US10676465B2/en active Active
- 2019-08-08 US US16/535,553 patent/US10683281B2/en active Active
2020
- 2020-12-01 NI NI202000091A patent/NI202000091A/es unknown
- 2020-12-02 PH PH12020552069A patent/PH12020552069A1/en unknown
- 2020-12-04 EC ECSENADI202078651A patent/ECSP20078651A/es unknown
- 2020-12-04 ZA ZA2020/07572A patent/ZA202007572B/en unknown
- 2020-12-07 CO CONC2020/0015305A patent/CO2020015305A2/es unknown
- 2020-12-11 CL CL2020003222A patent/CL2020003222A1/es unknown
2021
- 2021-02-09 US US17/171,385 patent/US20210163455A1/en not_active Abandoned
2023
- 2023-07-19 CY CY20231100347T patent/CY1126097T1/el unknown
- 2023-10-09 US US18/483,311 patent/US20240059679A1/en active Pending

Also Published As

Publication number	Publication date
NI202000091A (es)	2021-03-23
US20210163455A1 (en)	2021-06-03
MD3806955T3 (ro)	2024-01-31
EP3806955A1 (en)	2021-04-21
CA3045644A1 (en)	2019-12-13
UY38261A (es)	2020-01-31
US10934279B2 (en)	2021-03-02
CU20200099A7 (es)	2021-08-06
US10683281B2 (en)	2020-06-16
IL279300A (en)	2021-01-31
RS64323B1 (sr)	2023-08-31
AU2019285491B2 (en)	2021-11-11
IL279300B2 (en)	2023-11-01
CR20200612A (es)	2021-01-20
HRP20230631T1 (hr)	2023-09-29
DK4219487T3 (da)	2025-02-03
CN119462622A (zh)	2025-02-18
SI3806955T1 (sl)	2023-08-31
CN119431342A (zh)	2025-02-14
US20190382384A1 (en)	2019-12-19
US20190382388A1 (en)	2019-12-19
HRP20250099T1 (hr)	2025-03-28
TW202015679A (zh)	2020-05-01
MX2020013625A (es)	2022-01-04
MD3806955T2 (ro)	2023-09-30
CN112533674A (zh)	2021-03-19
AU2019285491A1 (en)	2020-12-17
PT3806955T (pt)	2023-07-20
EP3806955B9 (en)	2023-08-23
CL2020003222A1 (es)	2021-04-30
JP2021521265A (ja)	2021-08-26
CN112533674B (zh)	2024-11-15
NZ770240A (en)	2023-07-28
UA124371C2 (uk)	2021-09-01
RU2769715C1 (ru)	2022-04-05
LT4219487T (lt)	2025-01-27
PE20240584A1 (es)	2024-03-21
US20240059679A1 (en)	2024-02-22
SG11202011465QA (en)	2020-12-30
KR102542199B1 (ko)	2023-06-13
EP4219487B1 (en)	2024-12-18
JP6916968B1 (ja)	2021-08-11
EP3806955B1 (en)	2023-05-31
EP4219487A1 (en)	2023-08-02
DK3806955T3 (da)	2023-06-26
RS64323B9 (en)	2023-11-30
CO2020015305A2 (es)	2021-03-08
PH12020552069A1 (en)	2021-05-31
HUE063074T2 (hu)	2023-12-28
US10676465B2 (en)	2020-06-09
TWI707683B (zh)	2020-10-21
CN119462621A (zh)	2025-02-18
LT3806955T (lt)	2023-07-10
US20190382387A1 (en)	2019-12-19
CA3045644C (en)	2024-01-16
PL3806955T3 (pl)	2023-09-04
RS66418B1 (sr)	2025-02-28
ES2949954T3 (es)	2023-10-04
BR112020024470A2 (pt)	2021-03-02
FI4219487T3 (fi)	2025-02-24
CY1126097T1 (el)	2023-11-15
FI3806955T3 (fi)	2023-07-27
PE20211601A1 (es)	2021-08-18
GEP20237453B (en)	2023-01-10
IL279300B1 (en)	2023-07-01
EP4219487B9 (en)	2025-03-26
ZA202007572B (en)	2023-10-25
KR20210019529A (ko)	2021-02-22
ECSP20078651A (es)	2021-01-29
ES2949954T9 (es)	2023-11-23
WO2019239319A1 (en)	2019-12-19

Publication	Publication Date	Title
IL279300A (en)	2021-01-31	1-GLP agonist receptors and their use
IL279224A (en)	2021-01-31	1-GLP agonist receptors and their use
ZA201904616B (en)	2021-05-26	Glp-1 receptor agonists and uses thereof
IL283322A (en)	2021-07-29	glp-1r agonists and uses thereof
EP4059929A4 (en)	2023-11-01	GLP-1 RECEPTOR AGONIST AND ITS USE
IL269065A (en)	2019-11-28	Paranoid X receptor agonists and uses thereof
IL269068A (en)	2019-11-28	Paranoid X receptor agonists and uses thereof
IL281475A (en)	2021-04-29	Paranoid X receptor agonists and uses thereof
IL273253A (en)	2020-04-30	Glucagon-like peptide-1 receptor agonists and their uses
IL281471A (en)	2021-04-29	Farnesoid x receptor agonists and uses thereof
IL281474A (en)	2021-04-29	Farnesoid x receptor agonists and uses thereof
EP3445769A4 (en)	2020-02-12	THYROID HORMONE RECEPTOR AGONIST AND ITS USE
GB201811757D0 (en)	2018-08-29	Composition comprising GLP-1 receptor agonist and glucagon receptor agonist and application thereof
ZA202209312B (en)	2023-06-28	Glp-1r agonists and uses thereof
GB201817943D0 (en)	2018-12-19	Galanin-2 receptor agonists
GB201816650D0 (en)	2018-11-28	GLP-1 Receptor antagonists